Sorina Alina Cristea, Doina Catrinoiu and L. R. Craciun
Background: The last International Diabetes Federation statement showed that in 2015, there were 415 million people diagnosed with diabetes and the expectation for 2040 is around 642 million people all over the world. Diabetes Mellitus is a disease associated with major negative consequences due to its acute and chronic complications with chronic hyperglycemia playing a major role.
Method: We are presenting a case of 52 year old male patient, known with Type 2 Diabetes Mellitus for 10 years without treatment due to personal decision, who was admitted through the Emergency Unit in Neurology Department for bilateral myalgia of hips and arms, proximal force deficiency of bilateral lower limbs, acute retention of urine, fever, simptomatology which started about 48 before admission. The suspected diagnosis was acute polyradiculoneuritis but the paraclinical investigations performed on Neurology Unit excluded it and evaluated the present disease as Acute Diabetic Neuropathy. Through the passing days, the patient developed paraplegia and major unbalanced glycemic control (although he received multiple rapid human subcutaneous insulin injection) so they’ve decided to transfer him into Diabetology Department. At the moment of admission into Diabetology Unit, the patient had high fever, superficial and deep sensitivity disorders, urethral catheter and no faeces for 7 days. We’ve continued our investigations and came with a positive diagnosis of Unballanced and Complicated Type 2 Diabetes Mellitus with insulin therapy, Parainfectious Acute Transverse Myelitis, Prostatic and Seminal Vesicles Abces with rectal fistula, Sepsis, Acute Retention of Urine, Urina Infection with Pseudomonas Aeruginosa.
Conclusion: The diagnosis of Unballanced Diabetes Mellitus involves differential diagnosis due to lack of specific simptomatology in Diabetic Neuropathy and associated immune deficiency.
Background and Aims Diabetes mellitus (DM) represents a worldwide health problem and a major epidemic during the past decades. The exact number of people with diabetes in Romania is unknown. The aim of this paper was to determine the number of subjects registered with diabetes in Romania. Material and Method: The Romanian Society of Diabetes, Nutrition and Metabolic Diseases (RSDNMD) asked the representatives in charge with DM in each county about the total number of subjects registered with DM, the number of subjects with newly diagnosed DM in 2011 and their treatment (insulin or oral drugs). Results: There are 803,489 persons registered with DM, with a national prevalence of 4.21%. The lowest prevalence was observed in Ilfov (0.9%) and the highest prevalence (7.83%) in Bucharest. A total of 125,574 diabetics (15.62%) are treated only with insulin while 81,910 (10.19%) with combined insulin and oral medication. In 2011 have been registered 68.294 new cases of diabetes, with an incidence of 358.63/100,000 persons. The lowest incidence was 91.15 in Giurgiu county and the highest incidence was 718.94 in Arad county. Conclusions: There are large and unexplained differences between counties for both diabetes prevalence and incidence. Consequently, RSDNMD decided to start a national epidemiological study (PREDATORR) that will be carried out in 2013.
Mihaela Vladu, Diana Clenciu, Mihaela Bîcu and Maria Mofa
Background and Aims: Diabetes mellitus (DM) is a chronic disease which can evolve towards devastating micro and macro-vascular complications. Chronic kidney disease (CKD) is a worldwide public health problem, with adverse outcomes of kidney failure, cardiovascular disease (CVD) and premature death. The aim of our study was to evaluate the prognosis in patients with DM and CKD, depending on estimated glomerular filtration rate (eGFR) and albuminuria, according to the classification of Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (KDIGO) from 2013 Materials and Methods: The study was epidemiological, transversal, non interventional type, with 600 subjects unselected patients divided into three subgroups: 200 patients with T1DM, 200 patients with T2DM and 200 age matched subjects without DM. The recorded data have been analyzed using the Statistic Package for Social Sciences (SPSS), the 17.00 software (IBM Corporation, Armonk, NY, United States of America). Results:. We found a statistically significant difference among the three study groups (p < 0.0001) regarding the prognosis of CKD. Conclusions: DM represents an important risk factor for the appearance of CKD but also a negative prognosis factor for the patients with CKD.
F. Casoinic, D. Sampelean, Anca D. Buzoianu, N. Hancu and Dorina Baston
screen-detected diabetes? Diabet Med. 2008; 25(12):1433-1439.
21. WU YT, CHIEN CL, WANG SY, YANG WS, WU YW. Gender differences in myocardial perfusion defect in asymptomatic postmenopausal women and men with and without diabetesmellitus. J Women Health. 2013; 22(5):439-444.
22. GAMBINO R, MUSSO G, CASSADER M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2011; 15(5):1325-1365.
23. ROMBOUTS K, MARRA F. Molecular mechanisms of hepatic
D Popović, J Nikolajević Starčević, M Šantl Letonja, J Makuc, A Cokan Vujkovac, H Reschner, D Bregar and D Petrovič
models [ 21 , 25 ]. The purpose of this study was to investigate an association between the rs668 (+373C/G) polymorphism of the PECAM-1 gene and subclinical markers of carotid atherosclerosis in patients with type 2 diabetesmellitus (T2DM).
Patients and Methods
This study included 595 consecutive subjects with T2DM, admitted to the diabetes outpatient clinics of the general hospitals at Murska Sobota and Slovenj Gradec, Slovenia, and from the outpatient department at the Medical Center Medicor, Ljubljana, Slovenia. The inclusion criteria for the control
Jiangeng Han, Xin Wang, Zheng Chen, Ning Gao and Chen Wang
D., Kanavidis P., Machairas A., Current concepts in the management of necrotizing fasciitis, Front. Surg., 2014, 1, 36-45. 25593960 Misiakos E. Bagias G. Patapis P. Sotiropoulos D. Kanavidis P. Machairas A. Current concepts in the management of necrotizing fasciitis Front. Surg 2014 1 36 – 45
 Ogawa A., Shikata K., Uchida H.A., Shinoura S., Yokomichi N., Ogawa D., Case of emphysematous cholecystitis in a patient with type 2 diabetesmellitus associated with schizophrenia, J. Diabetes Investig., 2012, 3(6), 534-535. 10.1111/j
Raza S.T., Abbas S., Ahmad A., Ahmed F., Zaidi Z.H. and Mahdi F.
4. Opara EC. Oxidative stress, micronutrients, diabetesmellitus and its complications. J R Soc Promot Health. 2002; 122(1): 28-34.
5. Friedly LE, Philipson LH. Oxidative reactive species in cell injury: Mechanism in diabetesmellitus and therapeutic approaches. Ann N Y Acad Sci 2005; 1066: 136-151.
6. Bekris LM, Shephard C, Peterson J, Hoehna B, Van Yserloo E, Rutledge F, et al. Glutathionestransferase M1 and T1 polymorphisms and associations with type 1 diabetes age-at-onset. Autoimmunity. 2005; 38(8): 567-575.
Kamal Deep Joshi, Jeevan Ramachandra Galagali and Sanajeet Kumar Singh
1. Mohan V, Sandeep S, Deepa R, Shah B, Verghese C . Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 125: 217-230, 2007.
2. Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053, 2004.
3. Maia CAS, Campos CAH . Diabetesmellitus as etiological factor of hearing loss. Braz J Otorhinolaryngol 71: 208-214, 2005.
4. Xipeng L, Ruiyu L, Meng L, Yanzhuo Z, Kaosan G, Liping W. Effects of diabetes on hearing
Carmen Dobjanschi and Rucsandra Dănciulescu Miulescu
1. World Health Organisation .1999. Definition, diagnosis and classification of diabetesmellitus and its complications. WHO/NCD/NCS/99.2 ed.Geneva : World Health Organisation
2. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP et al. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358: 1991–2002, 2008.
3. Cheung NW, Oats JJ, McIntyre HD . Australian carbohydrate intolerance study in pregnant women: implications for the management of gestational diabetes. Aust N Z J
AIM: This work was done to study the effect of both types of diabetes mellitus (DM) on myocardial contractility in rats. Also, we investigated the role of treatment of DM with insulin and rosiglitazone (used as treatment for type 1 and type 2 DM respectively) in improvement of myocardial dysfunction in diabetic rats.
METHODS: The study included 50 male Wistar albino rats, divided into 5 groups: control (group I), streptozotocin induced type 1 DM (group II), fructose induced type 2 DM (group III), insulin treated type 1 diabetic rats (group IV) and rosiglitazone treated type 2 diabetic rats (group V). At the end of the study, retro-orbital blood samples were withdrawn and blood glucose, plasma triglyceride (TG), total cholesterol (TC) and thyroid hormones levels were measured. Rats were then anesthetized and their hearts were excised and connected to Langendorff apparatus to perform mechanical cardiac performance tests including heart rate (HR), left ventricular developed pressure (LVDP) and maximum rate of pressure rise (+dp/dt). RESULTS: Data of the study showed that relative to control group, there was significant increase in blood glucose, plasma TG and TC levels while, thyroid hormones and myocardial performance parameters showed significant decrease in both type 1 and type 2 diabetic rats. Treatment of type 1 diabetic rats with insulin and type 2 with rosiglitazone resulted in significant decrease in blood glucose, plasma TG and TC levels associated with significant improvement in thyroid hormones and myocardial performance parameters. The results also showed that insulin treatment of type 1 was more effective in ameliorating all parameters than treatment of type 2 by rosiglitazone.
CONCLUSION: We concluded that the induction of both types of diabetes resulted in decreased myocardial performance parameters. The treatment of type 1 and type 2 diabetes by insulin and oral rosiglitazone respectively improved to a great extent the altered metabolism and mechanical myocardial parameters, with more improving effect of insulin in type 1 than rosiglitazone in type 2 DM.